Presentation: P02004

There is currently a trend to develop cell based high content assays for resolving bottlenecks between discovery and lead optimization. In the central nervous system (CNS) most lead optimization still involves the use of animal models as simple in-vitro systems do not reflect the characteristics of brain pathophysiology. In-vivo CNS models are highly labor intensive and are particularly unable to cope with the numbers of lead candidates from High Throughput Screening.

We have developed a series of tissue culture based organotypic models for high content screening in neurodegenerative diseases. These models are based on ex-vivo brain tissues which can be used to determine structure-biological activity relationships and predict in vivo efficacy and safety. This new technology has the potential to act as an effective filter between lead candidates and preclinical development helping to significantly reduce attrition at an early stage.

Close Window X